Several studies implicate dysregulation of the ADAMTS-13/VWF axis as playing a major role
in vaso-occlusive events (VOE) in SCD. Another highlight is reducing iron overload, which …

For decades, it was considered that plasma kallikrein's (PKa) sole function within the
coagulation cascade is the activation of factor (F) XII. Until recently, the two key known …

Sickle cell disease (SCD) is a hereditary hemoglobinopathy marked by hemolytic anemia
and vaso-occlusive events (VOE). Chronic endothelial activation, inflammation, and …

The root cause of sickle cell disease (SCD) has been known for nearly a century, however,
few therapies to treat the disease are available. Over several decades of work, with …

Coagulation activation in immunothrombosis involves various pathways distinct from
classical hemostasis, offering potential therapeutic targets to control inflammation-induced …

A traumatic hemorrhage is fatal due to the great loss of blood in a short period of time;
however, there are a few biomaterials that can stop the bleeding quickly due to the limited …

Sickle cell disease (SCD) arises from beta‐globin gene mutations, with global estimates
indicating around 500 000 affected neonates in 2021. In the United States, it is considered …

Pressing concerns for patients with SCD include acute painful vaso-occlusive crises (VOC)
that frequently require hospitalization, along with stroke and venous thrombosis. Although …

Abstract Hemoglobin (Hb) Volga is a rare, unstable β-chain hemoglobin variant (β27 Ala→
Asp), causing chronic hemolytic anemia. This study presents two members of a Danish …

Despite arising from alterations in just one gene (beta-globin), sickle cell disease (SCD)
manifests in a plethora of complex, varied, and challenging-to-manage phenotypes …